Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer

Abstract

Background:

In an era of personalized medicine, individualized risk assessment using easily available tools on the internet and the literature are appealing. However, uninformed use by clinicians and the public raises potential problems. Herein, we assess the performance of published models to predict insignificant prostate cancer (PCa), using a multi-national low-risk population that may be considered for active surveillance (AS) based on contemporary practice.

Methods:

Data on men suitable for AS but undergoing upfront radical prostatectomy were pooled from three international academic institutions in Cambridge (UK), Toronto (Canada) and Melbourne (Australia). Four predictive models identified from literature review were assessed for their ability to predict the presence of four definitions of insignificant PCa. Evaluation was performed using area under the curve (AUC) of receiver operating characteristic curves and Brier scores for discrimination, calibration curves and decision curve analysis.

Results:

A cohort of 460 men meeting the inclusion criteria of all four nomograms was identified. The highest AUCs calculated for any of the four models ranged from 0.618 to 0.664, suggesting weak positive discrimination at best. Models had best discriminative ability for a definition of insignificant disease characterized by organ-confined Gleason score 6 with a total volume 0.5 ml or 1.3 ml. Calibration plots showed moderate range of predictive ability for the Kattan model though this model did not perform well at decision curve analysis.

Conclusions:

External assessment of models predicting insignificant PCa showed moderate performance at best. Uninformed interpretation may cause undue anxiety or false reassurance and they should be used with caution.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981–990.

    Article  Google Scholar 

  2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125–132.

    Article  Google Scholar 

  3. Epstein JI, Walsh P.C., Carmichael M, Brendler CB . Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. Clev Clin J Med 1994; 271: 368.

    CAS  Google Scholar 

  4. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP . Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933.

    Article  CAS  Google Scholar 

  5. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A . Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126–131.

    Article  Google Scholar 

  6. Bangma C, Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y et al. Active surveillance for low-risk prostate cancer worldwide: The PRIAS Study. Eur Urol 2012; 63: 597–603.

    PubMed  Google Scholar 

  7. Wong L-M, Alibhai SMH, Trottier G, Timilshina N, Van der Kwast T, Zlotta A et al. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. Eur Urol 2013; 66: 406–413.

    Article  Google Scholar 

  8. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185–2190.

    Article  Google Scholar 

  9. Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2011; 185: 477–482.

    Article  Google Scholar 

  10. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956–960.

    Article  Google Scholar 

  11. Wong L-M, Johnston R, Sharma N, Shah N, Warren A, Neal DE . General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. BJU Int 2012; 110: 24–27.

    Article  Google Scholar 

  12. Wong L-M, Neal DE, Johnston RB, Shah N, Sharma N, Warren AY et al. International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. Br J Cancer 2012; 107: 1467–1473.

    Article  Google Scholar 

  13. Steyerberg EW, Roobol MJ, Kattan TH, van der Kwast TH, Koning HJ, Schröder FH . Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177: 107–112.

    Article  CAS  Google Scholar 

  14. Nakanishi H, Wang X, Ochiai A, Trpkov K, Yilmaz A, Donnelly JB et al. A nomogram for predicting low-volume/low-grade prostate cancer. A tool for selecting patients for active surveillance. Cancer 2007; 110: 2441–2447.

    Article  Google Scholar 

  15. O’Brien BA, Cohen RJ, Ryan A, Sengupta S, Mills J . A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance. J Urol 2011; 186: 1811–1817.

    Article  Google Scholar 

  16. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792–1797.

    Article  Google Scholar 

  17. Chun FK, Haese A, Ahyai SA, Walz J, Suardi N, Capitanio U et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008; 113: 701.

    Article  Google Scholar 

  18. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RCN, Hoedemaeker RF, Van Leenders GJLH et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121–125.

    Article  Google Scholar 

  19. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 228–234.

    Article  Google Scholar 

  20. Memorial Sloan-Kettering Cancer Center. Prostate Cancer. Prediction Tools. mskcc.org. 2013 (cited 2014 May 5). Available from http://www.mskcc.org/cancer-care/adult/prostate/prediction-tools.

  21. SWOP – The Prostate Cancer Research Foundation, Rotterdam. Calculate your prostate cancer risk - Risk Calculator 5. Roobol M, editor. prostatecancer-riskcalculator.com. Rotterdam; 2013 (cited 2014 May 5). Available from http://www.prostatecancer-riskcalculator.com/.

  22. Vickers AJ, Cronin AM . Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology 2010; 76: 1298–1301.

    Article  Google Scholar 

  23. Hanley JA, McNeil BJ . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.

    Article  CAS  Google Scholar 

  24. Vickers A, Elkin EB . Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565–574.

    Article  Google Scholar 

  25. Corcoran NM, Hong MK, Casey RG, Hurtado-Coll A, Peters J, Harewood L et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 2011; 108: E202–E210.

    Article  Google Scholar 

  26. Iremashvili V, Soloway MS, Pelaez LT, Rosenberg DL, Manoharan M . Comparative validation of nomograms predicting clinically insignificant prostate cancer. Urology 2013; 81: 1202–1208.

    Article  Google Scholar 

  27. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J . Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 1605–1612.

    Article  Google Scholar 

  28. Epstein JI, Allsbrook WCJ, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.

  29. Wang S-Y, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR . Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int 2014; 114: E18–E24.

    Article  Google Scholar 

  30. Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology, 2011 ed. 2011; 259: 775–784.

    Article  Google Scholar 

  31. Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 2013; 190: 496–501.

    Article  Google Scholar 

  32. Cooperberg M, Simko J, Falzarano S, Maddala T, Chan J, Cowan J et al. Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance. J Urol 2013; 189: e873.

    Google Scholar 

Download references

Acknowledgements

Princess Margaret Hospital Prostate Centre database was conceived and maintained by the very generous financial and support of the Weinbaum Family Foundation with administrative support by the Princess Margaret Cancer Centre Foundation. We acknowledge the support of The University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited. We acknowledge the support of the National Institute for Health Research, which funds the Cambridge Biomedical Research Centre, Cambridge, UK. We also acknowledge the support of the National Cancer Research Prostate Cancer: Mechanisms of Progression and Treatment (PROMPT) collaborative (grant code G0500966/75466), which has funded tissue and urine collections in Cambridge. We also acknowledge the support of the Cambridge Cancer Research Foundation. The Human Research Tissue Bank is supported by the NIHR Cambridge Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L-M Wong.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wong, LM., Neal, D., Finelli, A. et al. Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. Prostate Cancer Prostatic Dis 18, 137–143 (2015). https://doi.org/10.1038/pcan.2015.1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2015.1

This article is cited by

Search

Quick links